Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Non-clinical research and clinical development services

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept mnlk:PrepaidResearchAndDevelopmentExpense.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's non-clinical research and clinical development services.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's non-clinical research and clinical development services?
MoonLake Immunotherapeutics (MLTX) reported non-clinical research and clinical development services of $16.33M in Q1 2026.
How has MoonLake Immunotherapeutics's non-clinical research and clinical development services changed year-over-year?
MoonLake Immunotherapeutics's non-clinical research and clinical development services increased by 14.2% year-over-year, from $14.31M to $16.33M.
What is the long-term trend for MoonLake Immunotherapeutics's non-clinical research and clinical development services?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's non-clinical research and clinical development services has grown at a 137.3% compound annual growth rate (CAGR), from $547.59K to $17.36M.